

France Cancer Diagnostics Market 2013 Sales Forecasts, Supplier Shares, Competitive Strategies

https://marketpublishers.com/r/F59E4E41872EN.html

Date: August 2013

Pages: 585

Price: US\$ 5,360.00 (Single User License)

ID: F59E4E41872EN

Abstracts

Complete report \$6,700. DataPack (test volumes, sales forecasts, supplier shares) \$3,950.

Summary

This comprehensive report contains 585 pages, 95 tables, and presents analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the French cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the French cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Cancer Diagnostic Tests



ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

Sales and market shares of major suppliers, by individual cancer diagnostic test.

Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:

Hospitals

Commercial/Private Laboratories

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Cancer statistics, etiology and recent developments.

Current and Emerging Products

Review of over 200 current and emerging cancer diagnostic tests, including:
Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors



Lymphokines

Immunohistochemical Stains, and others.

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.



Potential market entry barriers and risks.

Contains 585 pages and 95 tables



Contents

I. INTRODUCTION

II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
 - 1. Breast Cancer
 - 2. Lung Cancer
 - 3. Colon and Rectum Cancer
 - 4. Prostate Cancer
 - 5. Stomach Cancer
 - 6. Leukemia
 - 7. Lymphoma
 - 8. Oral Cancer
 - 9. Skin Cancer
 - 10. Uterine Cancer
 - 11. Ovarian Cancer
 - 12. Bladder Cancer
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. Introduction
 - 2. Tumor Marker Classification
 - 3. ACTH
 - 4. Alpha-Fetoprotein (AFP)
 - 5. Beta-2 Microglobulin
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. Calcitonin
 - 10. Carcinoembrionic Antigen (CEA)
 - 11. Estrogen and Progesterone Receptors
 - 12. Ferritin
 - 13. Gastrin
 - 14. Human Chorionic Gonadotropin (HCG)
 - 15. Insulin
 - 16. NSE
 - 17. Occult Blood
 - 18. PAP Smear/HPV
 - 19. Prostatic Acid Phosphatase (PAP)



- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Tumor Markers
 - ADA
 - **B-Protein**
 - **PNP**
 - 5'-Nucleotidase
- 27. Oncogenes
 - Abl/abl-bcr
 - AIB1
 - BCL-2
 - BRCA1
 - **CD44**
 - C-fos
 - C-myb
 - C-myc
 - CYP-17
 - Erb-B
 - HPC1
 - N-myc
 - P40
 - P51
 - P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
- 28. Polypeptide Growth Factors
 - Basic Fibroblast Growth Factor
 - Beta-TGF
 - Cachectin (TNT)
 - Calmodulin
 - **ECFR**



Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18



DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen

HPA

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KA

Kinases

KP16D3

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)



Multiple Tumor Suppressor

Myosin

NEA-130

NMP22

OA-519

Opiod Peptides

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

SCCL

Selectin

Sialic Acid

Sialyl SSEA-1/SLX

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG

TPS

Troponin

Tubulin

VCAM

VEGF

Villen

- C. Instrumentation Review And Market Needs
- D. Current and Emerging Technologies
 - 1. Monoclonal and Polyclonal Antibodies
 - 2. Immunoassays
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)

Overview

ELISA



Immunofiltration

Particle-Membrane Capture Immunoassay

Enzyme Amplification

- d. Fluorescent Immunoassays
- e. Luminescence

Chemiluminescence

Bioluminescence

- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- e. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
 - a. Technology Overview
- b. Amplification Methods
- 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
 - a. CT
 - b. MRI
 - c. NMR
 - d. PET
 - e. Photonics Spectroscopy
- G. Personal Testing

III. FRANCE

- A. Executive Summary
- **B.** Business Environment
- C. Market Structure



D. Market Size, Growth and Major Suppliers Sales and Market Shares

X. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

XI. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XII. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

XIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

XIV. COMPETITIVE PROFILES

Abbott

AdnaGen



Agilent Technologies

Applied Gene Technologies

Arca/Nuvelo

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CellSearch

Cepheid

Correlogic Systems/Vermillion

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Epigenomics

Enterix

Enzo Biochem

Exact Sciences

Fujirebio/Innogenetics

Guided Therapeutics

Hologic/Gen-Probe

Kreatech

Kyowa Medex

Life Technologies

Mackay Life Sciences

Myriad Genetics

Nanogen Elitech

OncoLab

Ortho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen/Ipsogen

Quest Diagnostics

Radient Pharmaceuticals

Roche



Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Veridex

Wako Pure Chemicals

Wallac/PE

Zila

XV. APPENDIXES:

Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic

Technology and Applications

Appendix II: Assumed Currency Exchange Rates



List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: France, Total Cancer Diagnostic Test Volume and Sales

Forecast by Market Segment

France, Estimated Cancer Death Rates Per 100,000 Population

France, Laboratories Performing Tumor Marker Tests by Market Segment

France, Hospital Laboratories Performing Tumor Marker Tests by Bed Size

France, Commercial/Private Laboratories Performing Tumor Markers by Annual Test Volume



France, Total Tumor Marker Test Volume Forecast by Market Segment

France, All Market Segments Major Tumor Marker Test Volume Forecast

France, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test

France, Commercial/Private Laboratories Marker Test Volume Forecast

France, Total Tumor Marker Sales Major Tumor Forecast by Market Segment

France, All Market Segments Major Tumor Marker Sales Forecast by Test

France, Hospital Laboratories Major Tumor Marker Sales Forecast by Test

France, Commercial/Private Laboratories Cancer Diagnostics Market Forecast by Test

France, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment

France, AFP Test Volume and Diagnostics Sales Forecast by Market Segment

France, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

France, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment

France, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market

France, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment

France, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment

France, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment

France, CEA Test Volume and Diagnostics Sales Forecast by Market Segment

France, Colon-Specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment

France, Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment France, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

France, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment

France, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment

France, HCG Test Volume and Diagnostics Sales Forecast by Market Segment

France, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment

France, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment

France, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment

France, Lymphocyte Subtyping Test Volume And Diagnostics Sales Forecast by Market Segment

France, NSE Test Volume and Diagnostics Sales Forecast by Market Segment

France, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment

France, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment

France, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment

France, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

France, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment



France, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment

France, Progesterone Receptor Test Volume And Diagnostics Sales Forecast by Market Segment

France, PAP Test Volume and Diagnostics Sales Forecast by Market Segment France, PSA Test Volume and Diagnostics Sales Forecast by Market Segment France, S-100 Protein Test Volume and Sales Diagnostics Sales Forecast by Market Segment

France, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment France, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment France, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

France, TDT Test Volume and Diagnostics Sales Forecast by Market Segment France, Thymidine Kinase Test Volume And Diagnostics Sales Forecast by Market Segment

France, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

France, TPA Test Volume and Diagnostics Sales Forecast by Market Segment

France, Total Tumor Marker Sales By Major Suppliers

France, AFP Testing Market Diagnostics Sales by Major Supplier

France, CA 15-3 Testing Market Diagnostics Sales by Major Supplier

France, CA 19-9 Testing Market Diagnostics Sales by Major Supplier

France, CA 125 Testing Market Diagnostics Sales by Major Supplier

France, CEA Testing Market Diagnostics Sales by Major Supplier

France, NSE Testing Market Diagnostics Sales by Major Supplier

France, PAP Testing Market Diagnostics Sales by Major Supplier

France, PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: France Cancer Diagnostics Market 2013 Sales Forecasts, Supplier Shares, Competitive

Strategies

Product link: https://marketpublishers.com/r/F59E4E41872EN.html

Price: US\$ 5,360.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/F59E4E41872EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



